Revenue Recognition

6 Months Ended

Jun. 29, 2019

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations⁽¹⁾(in millions):



	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
U.S.	$	768.6	$	772.3	$	1,537.4	$	1,558.7
Europe⁽²⁾	315.8		344.3		656.7		706.2
All other countries⁽³⁾	64.6		69.8		129.4		138.5
	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $6.9 million and $12.1 million for the three and six months ended June 29, 2019, respectively, and $5.0 million and $10.4 million for the three and six months ended June 30, 2018, respectively.

(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

The following is a summary of our net sales by category (in millions):



	Three Months Ended				Six Months Ended
	June 29, 2019		June 30, 2018		June 29, 2019		June 30, 2018
CSCA⁽¹⁾
Cough/cold/allergy/sinus	$	120.9	$	109.3	$	253.5	$	250.8
Gastrointestinal	106.2		103.0		206.5		195.2
Infant nutritionals	85.5		109.2		181.5		212.6
Analgesics	88.2		92.2		177.0		185.9
Smoking cessation	77.0		71.2		143.8		137.1
Animal health	22.4		31.9		42.0		58.2
Vitamins, minerals and dietary supplements	3.9		4.3		7.3		7.3
Other CSCA⁽²⁾	78.0		75.8		152.3		151.4
Total CSCA	582.1		596.9		1,163.9		1,198.5
CSCI
Cough/cold/allergy/sinus	74.1		84.7		169.8		183.4
Lifestyle	81.2		86.1		162.7		175.8
Personal care and derma-therapeutics	69.2		79.7		135.2		155.3
Natural health and vitamins, minerals and dietary supplements	25.6		27.9		55.4		61.1
Anti-parasites	26.0		30.4		52.7		58.5
Other CSCI⁽³⁾	51.4		49.1		102.5		101.6
Total CSCI	327.5		357.9		678.3		735.7
Total RX	239.4		231.6		481.3		469.2
Total net sales	$	1,149.0	$	1,186.4	$	2,323.5	$	2,403.4

(1) Includes net sales from our OTC contract manufacturing business.


(2)	Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.


(3)	Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $65.8 million and $133.1 million for the three and six months ended June 29, 2019, respectively, and $77.1 million and $146.5 million for the three and six months ended June 30, 2018, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):



	Balance Sheet Location	June 29, 2019		December 31, 2018
Short-term contract assets	Prepaid expenses and other current assets	$	16.6	$	25.5